- Home
- TOPS vs AEON Comparison
TOPS vs AEON Comparison
Compare TOPS & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.73
HOLD
Current Price
$1.17
Company Overview
Basic Information| Metric | TOPS | AEON |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Greece | United States |
| Employees | N/A | 5 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 26.8M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | TOPS | AEON |
|---|---|---|
| Price | $3.73 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 341.7K | 69.1K |
| Earning Date | 10-07-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $0.38 |
| 52 Week High | $11.47 | $1.45 |
Technical Indicators
Market Signals| Indicator | TOPS | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 51.94 |
| Support Level | N/A | $0.69 |
| Resistance Level | $6.20 | $1.42 |
| Average True Range (ATR) | 0.74 | 0.10 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 10.82 | 58.88 |
Price Performance
Historical Comparison TOPS
AEON
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.